{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:28Z","timestamp":1787070988227,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is limited data with regard to the use of modified 5-fluoroural-leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) in terms of tolerance and enabling total mesorectal excision (TME) of locally advanced rectal adenocarcinomas (LARC) with high-risk characteristics (T4b status, signet ring histology etc) post standard neoadjuvant long course chemoradiation (NACTRT) or short course radiation (SCRT) and chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients with LARC from January 2018 to December 2020 receiving mFOLFIRINOX post NACTRT\/SCRT to facilitate TME were evaluated. The primary endpoint was assessment of grade 3 and grade 4 treatment related toxicity and TME rates. Event free survival (EFS), where event was defined as disease progression or recurrence post resection after mFOLFIRINOX, was calculated by Kaplan Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty-seven patients were evaluated with a median age of 33 years (Range:18-59), 45% T4b status, 96% radiological circumferential margin (CRM) involved (79% CRM positive post NACTRT\/SCRT), 43% extramural venous invasion (n=33) and 36% signet ring histology. 62% had received prior NACTRT and 38% had received SCRT with chemotherapy before receiving mFOLFIRINOX. The most common grade 3 and grade 4 treatment related side effects included diarrhoea (7%), anaemia (4%) and infections (4%). Intended duration of mFOLFIRINOX or beyond was completed in 94% of patients. 60% of patients underwent curative local resection with R0 resection rates of 100% (n=28) and pathological complete response rates of 21%. The most common surgeries done were exenterations and abdominoperineal in 22% and 17% patients respectively. With a median follow up of 19 months, 24 patients had recurred or progressed for a median EFS of 20 months [95% confidence interval (CI): 15-24].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerated and enables TME in a significant proportion of these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_225_22","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T15:02:38Z","timestamp":1711810958000},"page":"199-203","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and \u2018salvage\u2019 in patients with high risk locally advanced rectal cancers \u2013 tolerance and early outcomes"],"prefix":"10.4103","volume":"20","author":[{"given":"Ramjas","family":"Prajapati","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Engineer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanish","family":"Saklani","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Peelay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Manali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"R1-20260507","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-20260507","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO):A randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R3-20260507","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/jso.25064","article-title":"MRI-based EMVI positivity predicts systemic recurrence in rectal cancer patients with a good tumor response to chemoradiotherapy followed by surgery","volume":"117","author":"Cho","year":"2018","journal-title":"J Surg Oncol"},{"key":"R4-20260507","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02841860701802585","article-title":"The 'good', the 'bad', and the 'ugly'rectal cancers","volume":"47","author":"Blomqvist","year":"2008","journal-title":"Acta Oncologica"},{"key":"R5-20260507","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2012.45.3258","article-title":"Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence:5-year follow-up results of the MERCURY study","volume":"32","author":"Taylor","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20260507","doi-asserted-by":"crossref","first-page":"958","DOI":"10.21037\/jgo.2016.08.11","article-title":"Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?","volume":"7","author":"Ostwal","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R7-20260507","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1634\/theoncologist.2016-0396","article-title":"Systemic chemotherapy as salvage treatment for locally advanced rectal cancer patients who fail to respond to standard neoadjuvant chemoradiotherapy","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"R8-20260507","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23):A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20260507","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification:From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"R10-20260507","first-page":"155","article-title":"Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients:Tertiary Indian cancer hospital experience","volume":"6","author":"Engineer","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"R11-20260507","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/jgo.2018.10.01","article-title":"Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes","volume":"10","author":"Ostwal","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"R12-20260507","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2013.54.9329","article-title":"Association of age with survival in patients with metastatic colorectal cancer:Analysis from the ARCAD clinical trials program","volume":"32","author":"Lieu","year":"2014","journal-title":"J Clin Oncol"},{"key":"R13-20260507","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41575-019-0253-4","article-title":"Early-onset colorectal cancer:Initial clues and current views","volume":"17","author":"Hofseth","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R14-20260507","doi-asserted-by":"crossref","first-page":"e2112539","DOI":"10.1001\/jamanetworkopen.2021.12539","article-title":"Analysis of survival among adults with early-onset colorectal cancer in the national cancer database","volume":"4","author":"Cheng","year":"2021","journal-title":"JAMA Network Open"},{"key":"R15-20260507","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R16-20260507","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20260507","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.31557\/APJCP.2020.21.6.1717","article-title":"Neoadjuvant FOLFIRINOX followed by chemoradiotherapy for middle and lower rectal cancer","volume":"21","author":"Sakr","year":"2020","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_225_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:00Z","timestamp":1787067600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_225_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_225_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"2022-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}